Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

 1.20p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.96
  • 52 Week Low: 0.88
  • Currency: UK Pounds
  • Shares Issued: 1,401.82m
  • Volume: 0
  • Market Cap: £16.82m
  • RiskGrade: 340
  • Beta: 0.73

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio
88.15% below the market average88.15% below the market average88.15% below the market average88.15% below the market average88.15% below the market average
58.14% below the sector average58.14% below the sector average58.14% below the sector average58.14% below the sector average58.14% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
87.27% above the market average87.27% above the market average87.27% above the market average87.27% above the market average87.27% above the market average
76.00% above the sector average76.00% above the sector average76.00% above the sector average76.00% above the sector average76.00% above the sector average
Price Chg 3m
79.78% above the market average79.78% above the market average79.78% above the market average79.78% above the market average79.78% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
65.09% above the market average65.09% above the market average65.09% above the market average65.09% above the market average65.09% above the market average
65.22% above the sector average65.22% above the sector average65.22% above the sector average65.22% above the sector average65.22% above the sector average
Momentum 20
40.61% above the market average40.61% above the market average40.61% above the market average40.61% above the market average40.61% above the market average
52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
44.4% below the market average44.4% below the market average44.4% below the market average44.4% below the market average44.4% below the market average
30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
76.6% below the market average76.6% below the market average76.6% below the market average76.6% below the market average76.6% below the market average
34.69% below the sector average34.69% below the sector average34.69% below the sector average34.69% below the sector average34.69% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
72.38% below the market average72.38% below the market average72.38% below the market average72.38% below the market average72.38% below the market average
57.45% below the sector average57.45% below the sector average57.45% below the sector average57.45% below the sector average57.45% below the sector average
Cash
54.08% below the market average54.08% below the market average54.08% below the market average54.08% below the market average54.08% below the market average
55.1% below the sector average55.1% below the sector average55.1% below the sector average55.1% below the sector average55.1% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 1.20p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.96
52 Week Low 0.88
Volume 0
Shares Issued 1,401.82m
Market Cap £16.82m
Beta 0.73
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
51.11% below the market average51.11% below the market average51.11% below the market average51.11% below the market average51.11% below the market average
72% below the sector average72% below the sector average72% below the sector average72% below the sector average72% below the sector average
Price Trend
6.02% above the market average6.02% above the market average6.02% above the market average6.02% above the market average6.02% above the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page